|
Name: Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid)
Type: Antidepressant
AKA: N/A
![Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) image](https://grammasearch.com/dev/v2/aiimages/amineptine_%287-%5B%2810%2C11-dihydro-5h-dibenzo%5Ba%2Cd%5Dcyclohepten-5-yl%29amino%5Dheptanoic_acid%29.png)
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
![Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) image](/dev/v2/pages/pubchem_images/2160.png)
|
|
IV. History
Amineptine, a stimulant and antidepressant, was developed in the 1960s by the French pharmaceutical company Servier. It was used to treat depression and was known for its stimulating effects. The drug's ability to increase dopamine levels in the brain made it effective for its intended use. However, amineptine's potential for abuse and addiction became evident, leading to its withdrawal from the market in many countries. The substance's history highlights the balance between therapeutic benefits and the risks of misuse, reflecting the broader challenges in the development and regulation of psychoactive medications.
|
|
V. Legal Information
Amineptine is an antidepressant with stimulant properties, previously used in several countries. Its legal status has changed, with many nations banning it due to concerns about abuse. In the United States, it is not approved for medical use and is considered illegal. Similar restrictions are observed globally to prevent misuse. [Source: UNODC].
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Amineptine is a stimulant and antidepressant with dopaminergic properties. It acts as an upper, enhancing mood and energy. Short-term use can improve mood, but long-term use may cause dependence and potential cognitive effects. Overdose risks include severe agitation and cardiovascular effects. Safe use involves cautious dosing. Recent research explores its efficacy in treating depression and associated health risks.  |
|
VII. Psychological Effects
Amineptine is an antidepressant with stimulating effects. Short-term use can enhance mood and cognition, while long-term use may lead to dependence and mood disturbances. Research indicates its impact on dopamine systems and associated risks.
 |
|
VIII. Culture
Amineptine is a stimulant and antidepressant with a unique pharmacological profile. Its cultural significance lies in its use as an antidepressant and its potential for abuse. Media coverage often addresses its efficacy, safety, and the issues surrounding its use. Amineptine is used medicinally and contributes to discussions about antidepressants and drug regulation.
 |